UK Health Service to Offer Semaglutide to High-Risk Patients The United Kingdom’s National Health Service (NHS) is expanding access to semaglutide, primarily marketed as Wegovy and Ozempic, to include individuals with obesity and a heightened risk of cardiovascular disease. This move represents a significant step in the nation’s approach to managing chronic conditions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is already widely used to facilitate weight loss. However, recent research indicates the drug’s benefits extend beyond simply reducing body mass. Studies have demonstrated that semaglutide provides protection for the heart and blood vessels, even prior to noticeable changes in weight. The NHS decision reflects growing evidence suggesting that semaglutide can positively impact cardiovascular health, potentially mitigating the risk of serious complications associated with obesity. Healthcare professionals will now be able to prescribe the medication to patients identified as being at elevated risk of heart disease due to their weight. This expansion of treatment options aims to address the significant public health challenge posed by obesity and its associated risks. Further research is ongoing to fully understand the long-term effects and optimal utilization of semaglutide in this expanded patient population. Topics: #heart #weight #loss Post navigation ANDRES INN⟩Operation “Darkness”: Inside information about the new union that plans to overthrow the Tsar Shadowy findings were discovered from the abandoned private jet of Jeffrey Epstein